Biochemical and Nutritional Changes During Continuous Subcutaneous Apomorphine Infusion in Advanced Parkinson’s Disease: Findings from an Observational Cohort
Objective: To evaluate the clinical effectiveness of CSAI and associated changes in vitamin B status, homocysteine (Hcy) levels, and nutritional outcomes in patients with advanced…Efficacy and Safety of Inhaled and Sublingual Apomorphine for On-Demand Treatment of OFF Episodes in Parkinson’s Disease: A Meta‑Analysis of Randomized Placebo‑Controlled Trials
Objective: To evaluate the efficacy and safety of inhaled (INH) and sublingual (SL) film apomorphine formulations for on-demand treatment of OFF episodes in Parkinson’s disease…When Presynaptic Stimulation is Not Enough: Severe Biphasic Dyskinesia on LECIG Reversed by Postsynaptic Apomorphine Rescue
Objective: To report an exceptional case of advanced Parkinson’s disease (PD) where levodopa/carbidopa/entacapone intestinal gel (LECIG) failed to provide adequate motor control, ultimately requiring a…Continuous Subcutaneous Apomorphine Infusion in Parkinson Disease: Final Data from the Multi-Year InfusON Open-Label Extension Study
Objective: Report outcomes from the multi-year extension to the 52-week open-label InfusON study (NCT02339064)1 of continuous subcutaneous apomorphine infusion (CSAI). Background: The US phase 3…APOSTIM study: a prospective study on quality of life in Parkinsonian patients sequentially treated with apomorphine infusion and STN stimulation
Objective: The APOSTIM study aimed to compare the quality of life (QoL) in Parkinson’s disease (PD) patients treated sequentially with continuous subcutaneous apomorphine infusion (CSAI)…Reduction in Dopaminergic Medication in Patients with Parkinson’s Disease Treated with Continuous Apomorphine Infusion versus Subthalamic Nucleus Deep Brain Stimulation: A Cohort Study
Objective: To compare the reduction in levodopa equivalent daily dose (LEDD) in patients with Parkinson’s disease treated with continuous subcutaneous apomorphine infusion versus bilateral subthalamic…Establishing Clinical Education and Patient Support Programs for Continuous Subcutaneous Apomorphine Infusion (CSAI) in the United States
Objective: Establish an educational “Master Class” program to prepare health care providers (HCPs) for CSAI availability in the U.S. and develop educational support for people…European Experience with Long-term Continuous Subcutaneous Apomorphine Infusions at Higher Doses
Objective: Outline European Union (EU) long-term experience with higher doses (≥6 mg/h or ≥100 mg/d) of continuous subcutaneous apomorphine infusion (CSAI). Background: The EU TOLEDO…Comparative Safety of Different Routes of Apomorphine Administration in Parkinson’s Disease: A Systematic Review and Meta-Analysis
Objective: To assess the safety profiles of inhaled, sublingual, and subcutaneous apomorphine in patients with Parkinson’s disease (PD). Background: Apomorphine is a direct-acting D1/D2 agonist…Continuous, Subcutaneous Apomorphine Infusion (CSAI) for PD: Development of a Phase IV routine practice study to capture the patient, care partner, and healthcare professional experience in the United States
Objective: To develop a Phase IV study that can be used to inform best practice when considering continuous, subcutaneous apomorphine infusion (CSAI) as a treatment…
- 1
- 2
- 3
- …
- 14
- Next Page »